HHS pauses enforcement of ban on compounding wellness peptides as FDA drafts new rules

HHS announced it will temporarily stop enforcing the existing prohibition on the compounding of certain peptides marketed for wellness.

The agency said the move is intended to protect consumer safety and personal freedom while the FDA works on specific regulations for these substances.

The pause will remain in place until the FDA completes its rulemaking process, after which normal enforcement is expected to resume.

Industry observers note the change could ease access for compounding pharmacies but also raise questions about oversight and product quality.